NDAINJECTIONINJECTABLEPriority Review
Approved
Dec 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
CERETEC (technetium tc-99m exametazime) by GE HealthCare is radiopharmaceutical activity [moa]. Approved for radioactive diagnostic agent [epc]. First approved in 1988.
Drug data last refreshed 20h ago
Mechanism of Action
Radiopharmaceutical Activity
Pharmacologic Class:
Radioactive Diagnostic Agent
Indications (1)
Company
Worked on CERETEC at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.